Infinity Pharmaceuticals, Inc.
INFI
INFI was delisted on the 13th of September, 2023.
66 hedge funds and large institutions have $59.6M invested in Infinity Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 12 closing their positions.
128% more call options, than puts
Call options by funds: $287K | Put options by funds: $126K
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
14% more capital invested
Capital invested by funds: $52.2M → $59.6M (+$7.38M)
13% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 15
3.9% more ownership
Funds ownership: 50.69% → 54.59% (+3.9%)
2% more funds holding
Funds holding: 65 → 66 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$3.75M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$1.96M |
| 3 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$763K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$681K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$618K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.87M |
| 2 |
MWNA
Marshall Wace North America
New York
|
-$841K |
| 3 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$445K |
| 4 |
Renaissance Technologies
New York
|
-$322K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$311K |
INFI Hedge Fund Activity: Q1 2018 in Review
66 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Infinity Pharmaceuticals, Inc. (INFI) for Q1 2018, worth a combined $59.6M — up 14% from $52.2M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new INFI positions and 12 closed out — a net gain of 2 holders — while 17 added to existing stakes and 15 trimmed.
The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $3.75M. The largest seller was Millennium Management, cutting an estimated $1.87M.
- 66 institutional investors held Infinity Pharmaceuticals, Inc. (INFI) as of Q1 2018, up from 65 in Q4 2017.
- Funds reported $59.6M of Infinity Pharmaceuticals, Inc. stock for Q1 2018, up 14% quarter-over-quarter.
- 14 funds opened new Infinity Pharmaceuticals, Inc. positions in Q1 2018 and 12 closed out, a net change of +2 holders.
- The largest Infinity Pharmaceuticals, Inc. buyer in Q1 2018 was Ghost Tree Capital, an estimated $3.75M added.
- The largest Infinity Pharmaceuticals, Inc. seller in Q1 2018 was Millennium Management, an estimated $1.87M sold.
Based on aggregated 13F filings for Q1 2018.